Luisa STAMM

Chief Medical Officer of Assembly Biosciences

USA

Biography of Luisa STAMM

Dr. Stamm joined Assembly as Chief Medical Officer in 2019.  She most recently served as a senior member of the HCV and HIV clinical research teams at Gilead Sciences, with responsibility for scientific and clinical development activities and overall research strategy. While at Gilead, she was Executive Director in the Liver Diseases Therapeutic Area, serving as project team leader of the development of two HCV therapeutics which are now marketed (VOSEVI® and EPCLUSA®), and Executive Director in the HIV and Emerging Viruses Therapeutic Area, focusing on the development of broadly neutralizing antibodies for HIV cure. In these roles, she supervised Phase 1, 2 and 3 clinical trials, and the filing of initial marketing applications in US, EU, Canada, China and Japan. Prior to Gilead, she was a Clinical Fellow and Instructor of Medicine at Harvard Medical School and Assistant in Medicine at Massachusetts General Hospital where she completed a clinical fellowship in infectious diseases and a post-doctoral research fellowship in bacterial pathogenesis. She is widely published in the areas of viral disease and microbial pathogenesis. Dr. Stamm received an MD and PhD in Biomedical Sciences from the University of California, San Francisco, and a BA in Biochemical Sciences from Harvard College